Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q4 FY23 Earnings Presentation
14 slides from Viyash Scientific's earnings presentation, May 23, 2023
Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences May 23, 2023 To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra‐Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip cod
Slide 2: Earnings Presentation Q4 & FY23
Earnings Presentation Q4 & FY23 24th May 2023 1
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Sequent announces Q4 FY23 results
Sequent announces Q4 FY 23 results. Company to restructure European operations In Q4 FY23, we have continued to make structural adjustments, so that we are present and ready to win in the most attractive markets and customer segments. Our recent actions are showing results. Despite the headwinds in
Slide 5: FY23: Overall growth of 2% in a challenging year
FY 23 : Overall growth of 2% in a challenging year ~10% cc growth for Emerging Markets Subdued sales of Formulations. delivered robust APIs Business growth of 16% cc, Mahad site awarded the restructuring in driving EcoVadis Sustainability Europe overall Formulations Silver Medal API : Focus on Top 1
Slide 6: Revenue performance by Geography
Revenue performance by Geography All values in ₹ Mn QoQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q4 FY23 Q3 FY23 QoQ Gr% Q4 FY22 YoY Gr% FY23 FY22 YoY Gr% (In cc) (In cc) (In cc) Formulations 2,559 2,588 (1.1%) (6.3%) 2,493 2.6% 2.9% 10,009 9,686 3.3% 9.9% Europe 1,146 1,050 9.1% 4.1% 1,024 11.9% 7.
Slide 7: Formulations: Sustaining growth momentum
Formulations : Sustaining growth momentum. Key Updates EUROPE- - Return to growth with launch of new Phyto range. Structural adjustments to improve margins FDFs 1000+ - Manufacturing in Germany discontinued and operations to shift to alternative low cost locations. - Margin accretive from Q3 FY 24 E
Slide 8: API: Continued strength in regulated markets
API : Continued strength in regulated markets Key Updates Pricing pressures and currency challenges in some markets had an adverse impact on Commercial 30+ demand APIs Regulated markets contribute ~ 72% of the revenue Strong portfolio- 8 fillings during the year . ( 5 USVMF + 3 CEPs ) API bu
Slide 9: Financials
oven Ability In Life Sciences J Seauent Financials
Slide 10: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q4 FY23 Q3 FY23 Q4 FY22 FY23 FY22 Particulars Unaudited Unaudited Unaudited Audited Audited Revenue from Operations 3,667 3,753 3,837 14,209 14,128 Material Consumption (2,217) (2,174) (2,188) (8,338) (7,930) Gross Margin 1,449 1,579 1,649 5,871 6,198 % 39.
Slide 11: Adjusted EBITDA at ₹110 crs
Adjusted EBITDA at ₹ 110 crs Amt in Rs Mn Particulars FY23 Revenue 14,209 EBITDA (Pre ESOP) 756 One offs 102 Improvement in Inventory days 60 Business restructuring 29 All values in ₹ Mn Turkey earthquake impact 13 Hyper inflation 28 Discontinued Operations in Germany 217 Adjusted EBITDA 1103 10
Slide 12: Key Balance sheet Items
Key Balance sheet Items All values in ₹ Mn Particulars Mar-23* Dec- 22* Mar-22`` Balance Sheet Highlights Shareholders Funds 6,981 7,715 6,919 Operational initiatives - working capital days Minority Interest 500 482 480 reduced by 11 days Net Debt 3,561 3,631 2,542 Net Debt is marginally down In
Slide 13: For details, feel free to contact
For details, feel free to contact: Krunal Shah Abhishek Singhal Nachiket Kale Company Secretary Investor Relations Consultant Investor Relations Advisor +91 22 4111 4779 abhishek.s@sequent.in +91 9920940808 investorrelations@sequent.in nachiket.kale@linkintime.co.in Registered Office: 301/A, ‘Dosti
Slide 14: Thank You
oven Ability In Life Sciences J Seauent Thank You